Valuation: Avalo Therapeutics, Inc.

Market Cap 95Cr 83Cr 77Cr 71Cr 134.12Cr 9.1TCr 136.46Cr 913.6Cr 357.81Cr 4.54TCr 358.68Cr 350.73Cr 15TCr P/E 2026 *
-7.31x
P/E 2027 * -6.04x
Enterprise Value 54Cr 47Cr 43Cr 40Cr 75Cr 5.1TCr 77Cr 512.34Cr 200.66Cr 2.55TCr 201.14Cr 196.69Cr 8.4TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.28%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-1.10%
1 week-7.44%
Current month-1.10%
1 month-4.19%
3 months+31.66%
6 months+13.10%
Current year-0.61%
1 week 17.75
Extreme 17.75
19.88
1 month 17.54
Extreme 17.54
20.65
Current year 12.51
Extreme 12.51
24.27
1 year 7.87
Extreme 7.87
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-7.44%+128.77%-61.98% 95Cr
+0.05%+3.08%+38.17%+66.77% 5.67TCr
-3.06%-8.56%+23.62%+58.73% 5.2TCr
+1.84%+1.27%-14.06%-13.50% 2.33TCr
-0.15%-6.00%-9.42%+344.47% 2.13TCr
-0.67%-3.25%+33.09%-29.84% 1.74TCr
+9.91%-2.51%+188.84%+326.19% 1.48TCr
+3.83%-1.34%+47.77%+165.22% 1.38TCr
+1.61%+0.56%+439.92%+166.12% 1.21TCr
+3.14%-12.56%+59.51%+149.39% 1.11TCr
Average +1.54%-2.84%+93.62%+117.16% 2.24TCr
Weighted average by Cap. +0.56%-1.97%+58.17%+107.67%

Financials

2026 *2027 *
Net sales - -
Net income -8.57Cr -7.45Cr -6.96Cr -6.39Cr -12Cr -817.07Cr -12Cr -82Cr -32Cr -407.46Cr -32Cr -31Cr -1.34TCr -11Cr -9.6Cr -8.96Cr -8.22Cr -16Cr -1.05TCr -16Cr -105.64Cr -41Cr -524.83Cr -41Cr -41Cr -1.73TCr
Net Debt -42Cr -36Cr -34Cr -31Cr -59Cr -4TCr -60Cr -401.26Cr -157.15Cr -1.99TCr -157.54Cr -154.05Cr -6.58TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.91TCr -44Cr -291.95Cr -114.34Cr -1.45TCr -114.62Cr -112.08Cr -4.78TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
03/26/03 $18.05 -1.10% 5,72,280
31/26/31 $18.25 -5.88% 9,23,877
30/26/30 $19.39 +2.00% 9,35,221
29/26/29 $19.01 -2.61% 7,89,787
28/26/28 $19.52 +0.10% 8,15,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.05USD
Average target price
44.69USD
Spread / Average Target
+147.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock